As of this morning, at $2.09 per share, we have added Cryoport (CYRX) to the Tailwinds Select Portfolio. Cryoport is in the business of shipping medicines. Any biologic that needs to be cryogenically suspended until it is dosed into a...
Tailwinds' Take: This transaction will provide the needed cash to see CYRX through to cash-flow positive, an event that will happen in either the last Q of this year or first of next. Once this transaction closes, I believe...
Tailwind's Take: this is a $2B market potentially and CYRX is the only pure play, fastest growing and best offering in the space. This could be a multi-year winner.  IRVINE, Calif., March 13, 2017 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW),...
Tailwind's Take: by publishing this index, investors in CYRX have a unique view into the growth of their industry. Expect this index to remain on the steep upslope for several years at a minimum.  IRVINE, Calif., Feb. 28, 2017 /PRNewswire/...
Tailwinds' Take: Moffitt is one of the leading cancer institutes in the US. Their selection of Cryoport is a major endorsement for the company as it looks to penetrate this growing market of biologics transportation. Expect more announcements like...